Contact information
Type
Scientific
Primary contact
Dr Ricardo Agurto-Rivera
ORCID ID
Contact details
Exequiel Fernández nº 920
Casa F
Ñuñoa
Santiago
Chile
+56 8 5021968
ricardo_agurto@yahoo.com
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
N/A
Study information
Scientific title
Acronym
Study hypothesis
TTT plus intravitreous triamcinolone are effective treatment for choroidal neovascularization and are better than TTT alone.
Ethics approval
Not provided at time of registration
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Condition
Age-Related Macular Degeneration (ARMD) not available for current therapies
Intervention
Complete ophthalmologic examination, treatment with TTT alone compared with treatment with TTT plus intravitreous Triamcinolone. Ophthalmologic control to verify closure of CNV or re-treatment.
Intervention type
Drug
Phase
Not Specified
Drug names
Triamcinolone
Primary outcome measures
Preservation of visual acuity
Secondary outcome measures
Closure of CNV, OCT characteristics
Overall trial start date
01/02/2004
Overall trial end date
28/02/2006
Reason abandoned
Eligibility
Participant inclusion criteria
Patients with severe ARMD (choroidal neovascularization [CNV]) that could not be treated with photodynamic therapy (PDT) because of bad prognosis or economical reasons.
Participant type
Patient
Age group
Not Specified
Gender
Not Specified
Target number of participants
200
Participant exclusion criteria
1. Any patient that has indication for PDT and has the economical means to get this therapy
2. Media opacity
3. Previous treatment for CNV
Recruitment start date
01/02/2004
Recruitment end date
28/02/2006
Locations
Countries of recruitment
Mexico
Trial participating centre
Exequiel Fernández nº 920
Santiago
Chile
Sponsor information
Organisation
Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)
Sponsor details
Vicente García Torres Nº 46
Barrio San Lucas
Del Coyoacán
Mexico City
04030
Mexico
+52 10841400
retinamex@yahoo.com
Sponsor type
Not defined
Website
Funders
Funder type
Charity
Funder name
Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
2005 results on http://www.ncbi.nlm.nih.gov/pubmed/16309554
Publication citations
-
Results
Agurto-Rivera R, Diaz-Rubio J, Torres-Bernal L, Macky TA, Colina-Luquez J, Papa-Oliva G, Jager RD, Martinez-Jardon S, Fromow-Guerra J, Quiroz-Mercado H, Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635]., BMC Ophthalmol, 2005, 5, 27, doi: 10.1186/1471-2415-5-27.